(Q38174649)

30 August 2017

Emerging drugs to treat obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

30 August 2017

1 reference

Stefano Pallanti

1

1 reference

30 August 2017

Giacomo Grassi

series ordinal

2

1 reference

30 August 2017

Andrea Cantisani

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

31 December 2013

1 reference

Expert Opinion on Emerging Drugs

30 August 2017

1 reference

30 August 2017

19

1 reference

30 August 2017

1

1 reference

30 August 2017

67-77

1 reference

The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication

30 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Research domain criteria (RDoC): toward a new classification framework for research on mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Dysfunctional reward circuitry in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

A meta-analysis of functional neuroimaging in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Increased right caudate nucleus size in obsessive-compulsive disorder: detection with magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Orbital Frontal and Amygdala Volume Reductions in Obsessive-compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

A.E. Bennett Research Award. Toward a neurodevelopmental model of of obsessive--compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Risk-dependent reward value signal in human prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Spontaneous alternation behavior: An animal model for obsessive-compulsive disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Five-year course of obsessive-compulsive disorder: predictors of remission and relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Prevalence of anti-basal ganglia antibodies in adult obsessive-compulsive disorder: cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

From Research Subgroup to Clinical Syndrome: Modifying the PANDAS Criteria to Describe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Gender differences in obsessive-compulsive symptom dimensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Plasma clomipramine levels in adult patients with obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

An update on the efficacy of psychological therapies in the treatment of obsessive-compulsive disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

The Yale-Brown Obsessive Compulsive Scale. II. Validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Clinical predictors of drug response in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Pharmacological management of treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Long-term follow-up study of patients with refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory meta-analysis of randomized and sham-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

The descriptive epidemiology of obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Quality of life in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Glutamatergic dysfunction in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Memantine as an augmenting agent for severe pediatric OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Memantine for treatment-resistant OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Memantine augmentation for refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

A single-blinded case-control study of memantine in severe obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Obsessive-compulsive disorder: subclassification based on co-morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Treatment non-response in OCD: methodological issues and operational definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Plasma fluvoxamine levels and OCD symptoms/response in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

Association Testing of the Positional and Functional Candidate Gene SLC1A1/EAAC1 in Early-Onset Obsessive-compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.875157

10.1517/14728214.2014.875157

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference